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Abstract
Tissue factor (TF) is the principal trigger of the coagulation cascade and involved in arterial thrombus
formation. Platelet-derived growth factor CC (PDGF-CC) is a recently discovered member of the PDGF
family released upon platelet activation. This study assesses the impact of PDGF-CC on TF expression
in human cells. PDGF-CC concentration-dependently induced TF expression by 2.5-fold in THP-1 cells,
by 2.0-fold in human peripheral blood monocytes, by 1.4-fold in vascular smooth muscle cells, and by
2.6-fold in microvascular endothelial cells, but did not affect TF expression in aortic endothelial cells. A
similar pattern was observed with PDGF-BB. In contrast, PDGF-AA did not alter TF expression in
THP-1 cells. TF whole cell activity was induced following stimulation with PDGF-BB and PDGF-CC in
THP-1 cells. Real-time polymerase chain reaction revealed that PDGF-CC induced TF mRNA.
PDGF-CC transiently activated p42/44 MAP kinase [extracellular signal-regulated kinase (ERK)], while
phosphorylation of the MAP kinases c-Jun NH(2)-terminal kinase (JNK) and p38 remained unaffected.
PD98059, a specific inhibitor of ERK phosphorylation, but not the p38 inhibitor SB203580 or the JNK
inhibitor SP600125 prevented PDGF-CC induced TF expression in a concentration-dependent manner.
The effect of PDGF-CC was antagonized by both PDGF receptor alpha and PDGF receptor beta
neutralizing antibodies; in contrast, PDGF-BB was only inhibited by PDGF receptor beta blocking
antibody. PDGF receptor alpha and PDGF receptor beta inhibition prevented PDGF-CC-induced ERK
phosphorylation. PDGF-CC induces TF expression via activation of alpha/beta receptor heterodimers
and an ERK-dependent signal transduction pathway.
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Abstract 
 
Background: Tissue factor (TF) is the principal trigger of the coagulation cascade 
and involved in arterial thrombus formation. Platelet-derived growth factor CC 
(PDGF-CC) is a recently discovered member of the PDGF family released upon 
platelet activation. This study assesses the impact of PDGF-CC on TF expression in 
human cells.  
Methods and Results: PDGF-CC concentration-dependently induced TF expression 
by 2.5-fold in THP-1 cells, by 2.0-fold in human peripheral blood monocytes, by 1.4-
fold in vascular smooth muscle cells, and by 2.6-fold in microvascular endothelial 
cells, but did not affect TF expression in aortic endothelial cells. A similar pattern was 
observed with PDGF-BB. In contrast, PDGF AA did not alter TF expression in THP-1 
cells. TF whole cell activity was induced following stimulation with PDGF BB and 
PDGF-CC in THP-1 cells. Real-time polymerase chain reaction revealed that PDGF-
CC induced TF mRNA. PDGF CC transiently activated p42/44 MAP kinase 
(extracellular signal-regulated kinase [ERK]), while phosphorylation of the MAP 
kinases c-Jun NH2-terminal kinase (JNK) and p38 remained unaffected. PD98059, a 
specific inhibitor of ERK phosphorylation, but not the p38 inhibitor SB203580 or the 
JNK inhibitor SP600125 prevented PDGF-CC induced TF expression in a 
concentration-dependent manner. The effect of PDGF-CC was antagonized by both 
PDGF receptor α and PDGF receptor β neutralizing antibodies; in contrast, PDGF-
BB was only inhibited by PDGF receptor β blocking antibody. PDGF receptor α and 
PDGF receptor β inhibition prevented PDGF-CC induced ERK phosphorylation. 
Conclusions: PDGF-CC induces TF expression via activation of α/β receptor 
heterodimers and an ERK–dependent signal transduction pathway. 
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Introduction 
 
Platelet-derived growth factor (PDGF) was originally identified as a mitogen for 
fibroblasts and vascular smooth muscle cells and has been linked to a number of 
human diseases. The PDGF family consists of at least 3 members signalling through 
the α- and/or β-PDGF receptor (PDGFR) tyrosine kinases. PDGF-CC, a recently 
discovered family member, is detectable at a high level in platelets, vascular smooth 
muscle cells, and microvascular endothelial cells [7, 28], and has been characterized 
as a potent angiogenic mediator. 
Tissue factor (TF), a 47 kDa transmembrane glycoprotein, is the main trigger 
of blood coagulation and plays a central role in thrombus formation. [27] Various 
mediators can induce TF in monocytes, endothelial cells, and vascular smooth 
muscle cells. [27] PDGF-BB, a well characterized member of the PDGF family, 
induces TF expression in monocytes and vascular smooth muscle cells. [6, 16, 23] 
However, PDGF-BB constitutes only about 7% of total PDGF activity in human 
serum, and the relative contribution of different PDGF isoforms to thrombus formation 
and acute vascular syndromes is unknown. [3] Moreover, PDGF-CC is released upon 
platelet activation and can be cleaved to its active form by plasmin or tissue-type 
plasminogen activator [7, 10, 18], suggesting a possible role at sites of thrombosis. 
Despite of these insights, potential prothrombotic properties of PDGF-CC remain 
poorly characterized. 
 Hence, this study examines the impact of PDGF-CC on TF expression in 
human cells. 
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Materials and Methods 
 
Cell culture 
 Human aortic endothelial cells (HAEC; Clonetics, Allschwil, Switzerland) were 
cultured as described. [26] Human microvascular endothelial cells (HMVEC; 
Clonetics) were kept in EGM-MV growth medium (Clonetics), THP-1 cells (LGC 
Promochem, Molsheim, France) in RPMI 1640 containing 25 mmol/L HEPES buffer 
and 10% FCS, and human aortic vascular smooth muscle cells (HAVSMC) in DMEM 
containing 10% FCS. Peripheral blood mononuclear cells were isolated from healthy 
subjects by density centrifugation in vacutainer cell preparation tubes with sodium 
heparin (Becton Dickinson, Franklin Lakes, NJ) and further purified by magnetic-
activated cell separation sorting with anti–human CD14 antibody (Miltenyi Biotec, 
Cologne, Germany) conjugated to magnetic beads. Purity was assessed by flow 
cytometry (FACSCanto, BD, Heidelberg, Germany) using FITC-conjugated anti–
human CD14 antibody (Miltenyi Biotec). Monocytes were cultured in RPMI 1640 
containing 25 mmol/L HEPES buffer and 10% FCS. Human monocytes and THP-1 
cells were rendered quiescent in starvation medium (0.5% FCS RPMI 1640) for 18 
and 24 hours, respectively. Adhering cells were grown to confluence in 3 cm dishes 
and rendered quiescent for 24 hours before stimulation with PDGF-AA, PDGF-BB, or 
PDGF-CC (all from R&D, Abingdom, UK) for 5 hours. SB203580 (Sigma, Buchs, 
Switzerland), PD98059 (Cell Signaling, Danvers, MA), and SP600125 (Calbiochem, 
Nottingham, UK) were added 60 minutes before stimulation. Antibodies blocking 
PDGF receptor α and PDGF receptor β (MAB 322 and AF 385; R&D Systems, 
Abingdon, UK) were added at 5 μg/mL and 1.25 μg/mL, respectively.  Cytotoxicity 
was assessed with a colorimetric assay to detect lactate dehydrogenase release 
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(Roche, Basel, Switzerland). [26] 
 
Western blot  
Protein expression was determined by Western blot analysis as described. 
[25] Cells were lysed in 50 mmol/L Tris buffer; 40 μg samples were loaded, separated 
by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis, and transferred 
to a polyvinylidene difluoride membrane (Millipore, Volketswil, Switzerland) by 
semidry transfer. Antibodies against human TF (American Diagnostica, Stamford, 
CA) were used at 1:2000 dilution. Antibodies against phosphorylated p38 MAP 
kinase (p38), phosphorylated p44/42 MAP kinase (extracellular signal regulated 
kinase [ERK]), and phosphorylated c-Jun NH2-terminal kinase (JNK; all from Cell 
Signaling) were used at 1000, 1:5000, and 1:1000 dilution, respectively. Antibodies 
against total p38, ERK, and JNK (all from Cell Signaling) were used at 1:2000, and 
1:1000 dilution, respectively. All blots were normalized to α-tubulin (aT) expression 
(1:20000 dilution, Sigma). [25]  
 
TF activity 
 TF activity was analyzed in THP-1 whole cell lysates using a colorimetric 
assay (American Diagnostica). TF/FVIIa converted factor X to factor Xa, which was 
measured by its ability to metabolize a chromogenic substrate. A standard curve with 
lipidated human TF was performed to assure that measurements were taken in the 
linear range of detection. 
 
Real-time PCR 
All real-time PCR experiments were performed in triplicate using the SYBR 
Green JumpStart kit (Sigma) in an MX3000P PCR cycler (Stratagene, Amsterdam, 
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The Netherlands). Each reaction (25 μl) contained 2 μl cDNA, 1 pmol of each primer, 
0.25 μl of internal reference dye, and 12.5 μl of JumpStart Taq ReadyMix (containing 
buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase, and JumpStart Taq 
antibody). The following primers were used: human tissue factor (F3): sense primer: 
5’-TCCCCAGAGTTCACACCTTACC–3’ (bases 508-529 of F3 cDNA; NCBI no. NM 
001993), antisense primer: 5’–TGACCACAAATACCACAGCTCC–3’ (bases 892-913 
of F3 cDNA; NCBI no. NM 001993); human L28: sense primer: 5’–
GCATCTGCAATGGATGGT-3’, antisense primer: 5’–TGTTCTTGCGGATCATGTGT-
3’. The amplification program consisted of 1 cycle at 95˚C for 10 min followed by 40 
cycles with a denaturing phase at 95˚C for 30 s, an annealing phase at 60˚C for 1 
min, and an elongation phase at 72˚C for 1 min. PCR products were analyzed on an 
ethidium bromide stained 1% agarose gel, and a melting curve analysis was 
performed after amplification to verify the accuracy of the amplicon. In each real-time 
PCR run for F3 and L28, a calibration curve was included that was generated from 
serial dilutions of the respective purified amplicon. [25]  
 
Statistics 
Data are presented as mean±SEM. Statistical analysis was performed by 2-
tailed unpaired Student’s t test or ANOVA as appropriate. A probability value of <0.05 
was considered significant. 
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Results 
 
PDGF-CC induces TF protein expression and activity 
THP-1 cells were stimulated with PDGF-CC, PDGF-BB, or PDGF-AA (0.1-10 
ng/ml) for 5 hours. PDGF-CC induced TF expression in a concentration-dependent 
manner with a maximal effect occurring at 10 ng/ml and resulting in a 2.5-fold 
induction as compared to unstimulated cells (n=9; p<0.05; Figure 1A). Similarly, 
PDGF-BB enhanced TF expression by 2.1-fold as compared to control (n=6; p<0.05; 
Figure 1B). In contrast, PDGF-AA did not affect TF expression (n=9; p=NS; Figure 
1C). The effect of PDGF-CC and PDGF-BB on TF protein expression in THP-1 cells 
was paralleled by an increased cellular TF activity 2.0-fold and 1.7-fold, respectively, 
at the maximal concentration (n=4; P<0.05; Figure 1D). 
Similar to THP-1 cells, PDGF-CC (1 - 10 ng/ml) induced TF expression in 
human peripheral blood monocytes by 2.1-fold (n=4; p<0.05; Figure 2A), in human 
microvascular endothelial cells by 2.5-fold (n=11; p<0.05; Figure 2B), and in human 
aortic vascular smooth muscle cells by 1.3-fold (n=5; p<0.05; Figure 2C). PDGF-BB 
(10 ng/ml) induced TF expression in human peripheral blood monocytes by 1.7-fold 
(n=4; p<0.05; Figure 2A), in microvascular endothelial cells by 1.7-fold (n=10; 
p<0.05; Figure 2B) and in human aortic vascular smooth muscle cells by 1.4-fold 
(n=5; p<0.05; Figure 2C). In contrast, PDGF-CC and PDGF-BB did not alter TF 
expression in human aortic endothelial cells (n=3; p=NS; Figure 2D).  
To control for toxic effects, cells were treated with PDGF-CC, -BB, or -AA for 5 
hours, and cell death was assessed by LDH release. No significant increase in LDH 
release was observed for any cell type and any concentration of PDGF used (n=4-15; 
p=NS; data not shown).  
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PDGF-CC induces TF mRNA expression 
Real-time PCR revealed that PDGF-CC (0.1 - 10 ng/ml) induced TF mRNA in 
THP-1 cells in a concentration-dependent manner with a maximal effect occuring at 
10 ng/ml (3.6-fold vs control; n=6; p<0.05; Figure 3). 
 
PDGF-CC induces TF via ERK activation 
To assess whether PDGF-CC activates MAP kinases, THP-1 cells were 
examined at different time points after PDGF-CC stimulation. ERK was transiently 
activated by PDGF-CC (10 ng/mL; n=3; p<0.05; Figure 4A), with maximal activation 
after 15 and 30 minutes. In contrast, phosphorylation of p38 and JNK remained 
unaffected as compared to control (n=3; p=NS; Figure 4B and 4C). Total expression 
of ERK, p38, and JNK remained unaltered at all time points examined (n=3; Figure 
4). To confirm a role for ERK activation in PDGF-CC induced TF expression, the 
effect of MAP kinase inhibitors on TF induction was examined. PD98059 (3x10-7 to 
3x10-6 mol/L), a specific inhibitor of ERK phosphorylation, inhibited PDGF-CC 
induced TF expression in a concentration-dependent manner (n=6; p<0.05; Figure 
5A). In contrast, SB203580 (10-6 to 10-5 mol/L), an inhibitor of p38 (n=3; p=NS; Figure 
5B) and SP600125 (10-7 to 10-6 mol/L), an inhibitor of JNK (n=4; p=NS; Figure 5C), 
did not affect PDGF-CC induced TF expression. No cytotoxic effect of either of these 
drugs was observed at any concentration used (n=3; P=NS; data not shown). 
 
PDGF-CC induces TF via α/β receptor heterodimer activation 
THP-I cells were pretreated with PDGF receptor blocking antibodies. The 
effect of PDGF-BB on TF expression was inhibited by blockade of PDGF receptor β, 
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but not PDGF receptor α (n=3; p=NS; Figure 6A). The effect of PDGF-CC on TF 
expression was inhibited by blockade of PDGF receptor α (n=3; p<0.05; Figure 6B) 
or PDGF receptor β (n=3; p<0.05; Figure 6B). No cytotoxic effect of either of these 
agents was observed at any concentration used (n=3; P=NS; data not shown). 
 
PDGF-CC-induced ERK phosphorylation depends on PDGFR α/β activation  
Transient activation of ERK by PDGF-CC was reversed by blocking of PDGF 
receptor α (n=6; p<0.05; Figure 6C) or PDGF receptor β (n=6; p<0.05; Figure 6C). 
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Discussion 
 
The PDGF family consists of four members, PDGF-A, -B, -C, and -D. [11, 17, 
19] Tissue factor (TF), a key mediator in thrombus formation [27], is induced in 
monocytes and vascular smooth muscle cells by PDGF-BB, a well characterized 
member of the PDGF family. [6, 16, 23] PDGF-CC, a newly discovered PDGF 
isoform, is secreted upon platelet activation, and latent PDGF-CC seems to be 
activated by locally released proteases of the fibrinolytic and coagulation systems, 
possibly at the site of ongoing thrombosis. [7, 10, 18] However, the prothrombotic 
potential of PDGF-CC remains poorly characterized. Therefore, this study analyzed 
for the first time the effect of PDGF-CC on TF expression in human cells. PDGF-CC 
induced TF expression in monocytes, microvascular endothelial cells, and vascular 
smooth muscle cells with a maximal response at 10 ng/mL. This effect occurred at 
the transcriptional level and was mediated through PDGF receptor (PDGFR)-α/β 
heterodimer dependent ERK phosphorylation.  
 Monocytes are present throughout atherosclerotic lesion progression [14]; 
moreover, monocytes seem to be the only blood cells capable of synthesizing TF. 
Hence, the present findings imply that PDGF-CC may modulate thrombus formation 
and propagation by activating monocytes. Since PDGF CC is mainly secreted by 
activated platelets, this effect may be particularly important under conditions of 
chronic platelet activation; such conditions have been associated with cardiovascular 
risk factors such as diabetes mellitus [4], smoking [21] and hyperlipidemia [1].  
The absence of PDGF receptors in endothelial cells derived from large vessels 
is well established,[2, 20] whereas microvascular endothelial cells express all PDGF 
receptors. [15, 20]  In line with this notion, the present study confirms that PDGF-BB 
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and PDGF-CC do not alter TF expression in HAECs even at high concentrations 
However, we show that TF expression was concentration-dependently enhanced in 
HMVECs upon stimulation with either isoform. Notably, in contrast to other vascular 
cells, the effect of PDGF CC on TF expression was significantly more potent as 
compared to that of PDGF-BB in HMVECs. Considering that TF is a candidate 
marker for the progression of microvascular disease in diabetic patients by its 
association with microvascular and neurogenic complications [24, 31], and that 
diabetes mellitus is associated with chronically increased platelet activation [4], the 
present data suggest that procoagulant activity in patients with ischemic 
microvascular complications may be triggered by PDGF-CC. 
 In the vessel wall, TF is constitutively expressed in subendothelial cells such 
as VSMCs cells leading to rapid initiation of coagulation when the vessel is damaged. 
[27] PDGF-CC induced TF expression in VSMC in a concentration-dependent 
manner. The rapid and potent induction of TF by PDGF-CC may be important in 
those conditions where VSMCs are exposed to activated platelets such as during 
thrombus formation and in those circumstances where VSMCs migrate such as 
atherosclerosis and neointimal hyperplasia after vascular intervention [9]. 
 Activated PDGF-CC is a high affinity ligand for PDGFR-α homodimers, while, 
in contrast to PDGF-BB, it fails to activate PDGFR-β homodimers. [12] Similar to 
PDGF-BB, PDGF-CC can activate PDGFR-α/β heterodimers in cells expressing both 
receptor isoforms. [12] To address the importance of α and β PDGF receptors in 
PDGF-CC induced TF expression, the isotype-matched monoclonal blocking Abs 
MAB 322 and AF 385 directed against α and β PDGF receptors, respectively, were 
applied. [8] In THP-1 cells, PDGFR-β blockade was found to prevent the stimulatory 
effects of PDGF-BB and PDGF-CC on TF expression. PDGFR-α blockade was 
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ineffective in inhibiting PDGF-BB induced TF expression, whereas TF expression in 
response to PDGF-CC was prevented. However, no stimulation of TF expression 
was observed after administration of PDGF-AA, the specific ligand for PDGFR-α/α 
homodimers. Taken together, these findings indicate an important role of PDGFR-a/β 
signalling in mediating prothrombotic actions, which has, until now, only been 
attributed to the PDGFR-β/β homodimer. Moreover our data support the conclusion 
that PDGFR-α/α homodimer signalling is not required for the prothrombotic effects of 
PDGFs in vascular cells, which supports previously published data. [11, 13, 17]  
 MAP kinase activation is a key element in regulating TF transcription in 
response to many stimuli. [27] It is well established that both PDGF-BB induced 
chemotaxis and TF induction depend on activation of extracellular signal-regulated 
kinase (ERK) [5, 16, 29, 30]. In the present study, rapid and transient activation of 
ERK was observed after stimulation by PDGF-CC, whereas JNK and p38 were not 
affected. Consistent with MAP kinase activation, the increase in TF protein 
expression by PDGF-CC was preceded by an enhanced TF mRNA expression. 
Inhibition of MAP kinases by specific inhibitors confirmed that PDCF-CC induced TF 
expression was strictly ERK dependent; moreover, PDGFR-α and PDGFR-β 
blockade prevented PDGF-CC induced ERK phosphorylation, which is consistent 
with PDGFR-α/β dependent signalling. In line with this notion, previous studies have 
described that the downstream signalling profile of PDGFR-β is largely ERK 
dependent[22], whereas the PDGFR-α/α homodimer may also be able to induce JNK 
in several cell lines [22].   
 In conclusion, these data represent the first evidence that PDGF-CC, a newly 
discovered member of the PDGF family, exerts prothrombotic actions via PDGFR-a/β 
signalling resulting in ERK dependent induction of TF expression and activity. The 
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ability of PDGF-CC to stimulate TF expression not only in monocytes, but also in 
microvascular endothelial cells suggests that it is involved in thrombotic 
microvascular complications. Hence, a better understanding of the action of PDGF-
CC may help refine strategies to prevent microvascular dysfunction. Further, PDGF-
CC may be relevant for VSMC migration in conditions such as neointimal hyperplasia 
after vascular intervention. 
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Figure legends 
 
Figure 1 
PDGF-CC (A.) and PDGF-BB (B.), but not PDGF-AA (C.), induced TF protein 
expression in THP-1 cells. Values are indicated as percent of control and 
representative of at least 4 different experiments; all blots are normalized to α-tubulin 
(aT) expression; *p<0.05 vs control. D. PDGF-BB and PDGF-CC induced TF whole 
cell activity in THP-1 cells; *p<0.05 vs control. 
 
Figure 2 
PDGF-CC induced TF protein expression in human peripheral blood monocytes (A.), 
human microvascular endothelial cells (B.) and human aortic vascular smooth 
muscle cells (C.), but not human aortic endothelial cells (D.). PDGF-BB is included as 
a positive control. Values are indicated as percent of control and representative of at 
least 3 different experiments; all blots are normalized to α-tubulin (aT) expression; 
*p<0.05 vs control. 
 
Figure 3 
PDGF-CC induced TF mRNA in THP-1 cells. Values are indicated as percent of 
control and representative of 6 different experiments; all blots are normalized to L28 
mRNA expression; *p<0.05 vs control. 
 
Figure 4 
PDGF-CC induced a transient activation of ERK (A) in THP-1 cells. No change in p38 
(B) and JNK (C) phosphorylation occurred. Total (Tot) levels of ERK, p38, and JNK 
remained unaltered. Values are representative of at least 3 different experiments. 
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Figure 5 
A. The specific inhibitor of ERK activation, PD98059, impaired PDGF-CC induced TF 
expression in THP-1 cells, while the p38 inhibitor SB203580 (B.) and the JNK 
inhibitor SP600125 (C.) did not affect TF. Values are representative of at least 3 
different experiments; all blots are normalized to α-Tubulin (aT) expression; *p<0.05 
vs PDGF-CC alone. 
 
Figure 6 
A. PDGF receptor β blocking antibody inhibited TF expression by PDGF-BB, while 
PDGF receptor α blocking antibody had no effect. *p<0.05 vs PDGF-BB alone. B. 
Both PDGF receptor α and receptor β blocking antibodies inhibited TF expression by 
PDGF-CC. * p<0.05 vs PDGF-CC alone. C. PDGF receptor α  blocking antibody and  
PDGF receptor β blocking antibody reversed PDGF-CC induced ERK 
phosphorylation. *p<0.05 vs PDGF-CC alone. Values are representative of at least 3 
different experiments; all blots are normalized to α-Tubulin (aT) expression and total 
ERK expression, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24  
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4  
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Figure 5 
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Figure 6 
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